Mesenchymal stem cells: A potential targeted-delivery vehicle for anti-cancer drug, loaded nanoparticles

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 2, 2013, Pages 174-184

  Gao, Zibin ^a   Zhang, Linan ^a   Hu, Jie ^b   Sun, Yongjun ^a  

^a HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Mesenchymal stem cells; Nanoparticle; Targeted delivery; Vehicle

Indexed keywords

ANTI-CANCER AGENTS; ANTI-CANCER THERAPIES; ANTICANCER DRUG; CANCER; CANCER GENE THERAPY; CELL-BASED; MESENCHYMAL STEM CELL; METASTATIC DISEASE; NANOPARTICLE (NPS); TARGETED DELIVERY; TARGETED DRUG DELIVERY SYSTEMS;

DISEASES; DRUG DELIVERY; FLOWCHARTING; NANOPARTICLES; TUMORS; VEHICLES;

CELL CULTURE;

ANTINEOPLASTIC AGENT; BUSULFAN; CELL PENETRATING PEPTIDE; CHITOSAN; CISPLATIN; CYCLOHEXYL(PHENYL)(2 PIPERIDINOETHYL)SILANOL; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; METHOTREXATE; NANOCOMPOSITE; NANOPARTICLE; PACLITAXEL; POLY(ETHYLENIMINE); POLYAMIDOAMINE; POLYLYSINE; POLYMER; TIOPRONIN; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; BIOCOMPATIBILITY; CANCER GENE THERAPY; CANCER RESISTANCE; CELL ISOLATION; CYTOTOXICITY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; ENDOCYTOSIS; HUMAN; IMMUNOGENICITY; INTERNALIZATION; MESENCHYMAL STEM CELL; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; PASSIVE TRANSPORT; REVIEW; STATIC ELECTRICITY; STEM CELL TRANSPLANTATION; SURFACE CHARGE; TUMOR MICROENVIRONMENT; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MESENCHYMAL STROMAL CELLS; NANOPARTICLES; NEOPLASMS;

EID: 84873707898     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.06.003     Document Type: Review

References (119)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
3. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007, 24:1-16.
4. Cukierman E., Khan D.R. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol 2010, 80:762-770.
5. Gabizon A.A. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 2001, 7:223-225.
6. Bedu-Addo F.K., Tang P., Xu Y., Huang L. Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: implications in liposomal drug delivery. Pharm Res 1996, 13:710-717.
7. Photos P.J., Bacakova L., Discher B., Bates F., Discher D.E. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 2003, 90:323-334.
8. Fukumura D., Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007, 74:72-84.
9. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010, 148:135-146.
10. Roby A., Erdogan S., Torchilin V.P. Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles. Cancer Biol Ther 2007, 6:1136-1142.
11. Matsumura Y., Gotoh M., Muro K., Yamada Y., Shirao K., Shimada Y., et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004, 15:517-525.
12. Hatakeyama H., Akita H., Kogure K., Oishi M., Nagasaki Y., Kihira Y., et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther 2007, 14:68-77.
13. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001, 19:424-436.
14. Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012, 64:739-748.
15. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65:3307-3318.
16. Studeny M., Marini F.C., Dembinski J.L., Zompetta C., Cabreira-Hansen M., Bekele B.N., et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004, 96:1593-1603.
17. Loebinger M.R., Eddaoudi A., Davies D., Janes S.M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009, 69:4134-4142.
18. Sasportas L.S., Kasmieh R., Wakimoto H., Hingtgen S., van de Water J.A., Mohapatra G., et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A 2009, 106:4822-4827.
19. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002, 62:3603-3608.
20. Porada C.D., Almeida-Porada G. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv Drug Deliv Rev 2010, 62:1156-1166.
21. Hu Y.L., Fu Y.H., Tabata Y., Gao J.Q. Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release 2010, 147:154-162.
22. Banerji S.K., Hayes M.A. Examination of nonendocytotic bulk transport of nanoparticles across phospholipid membranes. Langmuir 2007, 23:3305-3313.
23. Schulze E., Ferrucci J.T., Poss K., Lapointe L., Bogdanova A., Weissleder R. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest Radiol 1995, 30:604-610.
24. Lorenz M.R., Holzapfel V., Musyanovych A., Nothelfer K., Walther P., Frank H., et al. Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials 2006, 27:2820-2828.
25. Rejman J., Oberle V., Zuhorn I., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169.
26. Conner S.D., Schmid S.L. Regulated portals of entry into the cell. Nature 2003, 422:37-44.
27. Albarenque S.M., Zwacka R.M., Mohr A. Both human and mouse mesenchymal stem cells promote breast cancer metastasis. Stem Cell Res 2011, 7:163-171.
28. Wang L., Neoh K.G., Kang E.T., Shuter B., Wang S.C. Biodegradable magnetic-fluorescent magnetite/poly(dl-lactic acid-co-alpha, beta-malic acid) composite nanoparticles for stem cell labeling. Biomaterials 2010, 31:3502-3511.
29. Kim J.H., Park J.S., Yang H.N., Woo D.G., Jeon S.Y., Do H.J., et al. The use of biodegradable PLGA nanoparticles to mediate SOX9 gene delivery in human mesenchymal stem cells (hMSCs) and induce chondrogenesis. Biomaterials 2011, 32:268-278.
30. Sarkar D., Ankrum J.A., Teo G., Carman C.V., Karp J.M. Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms. Biomaterials 2011, 32:3053-3061.
31. Roger M., Clavreul A., Venier-Julienne M.C., Passirani C., Sindji L., Schiller P., et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 2010, 31:8393-8401.
32. Roger M., Clavreul A., Huynh N.T., Passirani C., Schiller P., Vessieres A., et al. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int J Pharm 2012, 423:63-68.
33. Wang W., Li B., Li Y., Jiang Y., Ouyang H., Gao C. In vivo restoration of full-thickness cartilage defects by poly(lactide-co-glycolide) sponges filled with fibrin gel, bone marrow mesenchymal stem cells and DNA complexes. Biomaterials 2010, 31:5953-5965.
34. Corsi K., Chellat F., Yahia L., Fernandes J.C. Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials 2003, 24:1255-1264.
35. Pimpha N., Sunintaboon P., Inphonlek S., Tabata Y. Gene delivery efficacy of polyethyleneimine-introduced chitosan shell/poly(methyl methacrylate) core nanoparticles for rat mesenchymal stem cells. J Biomater Sci Polym Ed 2010, 21:205-223.
36. Park J.W., Mok H., Park T.G. Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. J Control Release 2010, 142:238-244.
37. Liu G., Wang Z., Lu J., Xia C., Gao F., Gong Q., et al. Low molecular weight alkyl-polycation wrapped magnetite nanoparticle clusters as MRI probes for stem cell labeling and in vivo imaging. Biomaterials 2011, 32:528-537.
38. Park J.S., Na K., Woo D.G., Yang H.N., Kim J.M., Kim J.H., et al. Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells. Biomaterials 2010, 31:124-132.
39. Suh J.S., Lee J.Y., Choi Y.S., Yu F., Yang V., Lee S.J., et al. Efficient labeling of mesenchymal stem cells using cell permeable magnetic nanoparticles. Biochem Biophys Res Commun 2009, 379:669-675.
40. Park K.S., Tae J., Choi B., Kim Y.S., Moon C., Kim S.H., et al. Characterization, in vitro cytotoxicity assessment, and in vivo visualization of multimodal, RITC-labeled, silica-coated magnetic nanoparticles for labeling human cord blood-derived mesenchymal stem cells. Nanomedicine 2010, 6:263-276.
41. Tseng C.L., Shih I.L., Stobinski L., Lin F.H. Gadolinium hexanedione nanoparticles for stem cell labeling and tracking via magnetic resonance imaging. Biomaterials 2010, 31:5427-5435.
42. Liu M., Guo Y.M., Wu Q.F., Yang J.L., Wang P., Wang S.C., et al. Paramagnetic particles carried by cell-penetrating peptide tracking of bone marrow mesenchymal stem cells, a research in vitro. Biochem Biophys Res Commun 2006, 347:133-140.
43. Coupland P.G., Fisher K.A., Jones D.R., Aylott J.W. Internalisation of polymeric nanosensors in mesenchymal stem cells: analysis by flow cytometry and confocal microscopy. J Control Release 2008, 130:115-120.
44. Tautzenberger A., Lorenz S., Kreja L., Zeller A., Musyanovych A., Schrezenmeier H., et al. Effect of functionalised fluorescence-labelled nanoparticles on mesenchymal stem cell differentiation. Biomaterials 2010, 31:2064-2071.
45. Santos J.L., Oliveira H., Pandita D., Rodrigues J., Pego A.P., Granja P.L., et al. Functionalization of poly(amidoamine) dendrimers with hydrophobic chains for improved gene delivery in mesenchymal stem cells. J Control Release 2010, 144:55-64.
46. Higuchi Y., Wu C., Chang K.L., Irie K., Kawakami S., Yamashita F., et al. Polyamidoamine dendrimer-conjugated quantum dots for efficient labeling of primary cultured mesenchymal stem cells. Biomaterials 2011, 32:6676-6682.
47. Wang M., Deng W.W., Fu M., Cao X., Yang Y., Su W.Y., et al. Efficient gene transfer into rat mesenchymal stem cells with cationized Lycium barbarum polysaccharides nanoparticles. Carbohydrate Polymers 2011, 86:1509-1518.
48. Jo J., Aoki I., Tabata Y. Design of iron oxide nanoparticles with different sizes and surface charges for simple and efficient labeling of mesenchymal stem cells. J Control Release 2010, 142:465-473.
49. Yang H.N., Park J.S., Woo D.G., Jeon S.Y., Do H.J., Lim H.Y., et al. C/EBP-alpha and C/EBP-beta-mediated adipogenesis of human mesenchymal stem cells (hMSCs) using PLGA nanoparticles complexed with poly(ethyleneimmine). Biomaterials 2011, 32:5924-5933.
50. Park J.S., Yang H.N., Woo D.G., Jeon S.Y., Do H.J., Lim H.Y., et al. Chondrogenesis of human mesenchymal stem cells mediated by the combination of SOX trio SOX5, 6, and 9 genes complexed with PEI-modified PLGA nanoparticles. Biomaterials 2011, 32:3679-3688.
51. Wu G.Y., Wu C.H. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J Biol Chem 1987, 262:4429-4432.
52. Han S., Mahato R.I., Sung Y.K., Kim S.W. Development of biomaterials for gene therapy. Mol Ther 2000, 2:302-317.
53. Godbey W.T., Wu K.K., Mikos A.G. Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res 1999, 45:268-275.
54. Pack D.W., Hoffman A.S., Pun S., Stayton P.S. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005, 4:581-593.
55. Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem Rev 2009, 109:259-302.
56. Rao S.B., Sharma C.P. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res 1997, 34:21-28.
57. Richardson S.C., Kolbe H.V., Duncan R. Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm 1999, 178:231-243.
58. Fang N., Chan V., Mao H.Q., Leong K.W. Interactions of phospholipid bilayer with chitosan: effect of molecular weight and pH. Biomacromolecules 2001, 2:1161-1168.
59. Teijeiro-Osorio D., Remunan-Lopez C., Alonso M.J. Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur J Pharm Biopharm 2009, 71:257-263.
60. Klausner E.A., Zhang Z., Chapman R.L., Multack R.F., Volin M.V. Ultrapure chitosan oligomers as carriers for corneal gene transfer. Biomaterials 2010, 31:1814-1820.
61. Chung T.H., Wu S.H., Yao M., Lu C.W., Lin Y.S., Hung Y., et al. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 2007, 28:2959-2966.
62. Chang L.C., Lee H.F., Yang Z., Yang V.C. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization. AAPS PharmSci 2001, 3:E17.
63. Park Y.J., Chang L.C., Liang J.F., Moon C., Chung C.P., Yang V.C. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. Faseb J 2005, 19:1555-1557.
64. Munoz-Morris M.A., Heitz F., Divita G., Morris M.C. The peptide carrier Pep-1 forms biologically efficient nanoparticle complexes. Biochem Biophys Res Commun 2007, 355:877-882.
65. Morris M.C., Robert-Hebmann V., Chaloin L., Mery J., Heitz F., Devaux C., et al. A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains. J Biol Chem 1999, 274:24941-24946.
66. De Smedt S.C., Remaut K., Lucas B., Braeckmans K., Sanders N.N., Demeester J. Studying biophysical barriers to DNA delivery by advanced light microscopy. Adv Drug Deliv Rev 2005, 57:191-210.
67. Gao H., Shi W., Freund L.B. Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci U S A 2005, 102:9469-9474.
68. Panyam J., Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(D, L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res 2003, 20:212-220.
69. Jin H., Heller D.A., Sharma R., Strano M.S. Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. ACS Nano 2009, 3:149-158.
70. Chithrani B.D., Chan W.C. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 2007, 7:1542-1550.
71. Horák D., Babič M., Jendelová P., Herynek V., Trchová M., Likavčanová K., et al. Effect of different magnetic nanoparticle coatings on the efficiency of stem cell labeling. J Magn Magn Mater 2009, 321:1539-1547.
72. Akinc A., Thomas M., Klibanov A.M., Langer R. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 2005, 7:657-663.
73. Sonawane N.D., Szoka F.C., Verkman A.S. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem 2003, 278:44826-44831.
74. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb J 2002, 16:1217-1226.
75. Paillard A., Hindre F., Vignes-Colombeix C., Benoit J.P., Garcion E. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials 2010, 31:7542-7554.
76. Li J., Law H.K., Lau Y.L., Chan G.C. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol 2004, 127:326-334.
77. Cao J., Tan M.H., Yang P., Li W.L., Xia J., Du H., et al. Effects of adjuvant chemotherapy on bone marrow mesenchymal stem cells of colorectal cancer patients. Cancer Lett 2008, 263:197-203.
78. Kemp K., Morse R., Wexler S., Cox C., Mallam E., Hows J., et al. Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy. Ann Hematol 2010, 89:701-713.
79. Li J., Law H.K., Liu Y.L., Chan G.C. Effect of cisplatin, topotecan, daunorubicin and hydroxyurea on human mesenchymal stem cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010, 18:991-996.
80. Reyes M., Lund T., Lenvik T., Aguiar D., Koodie L., Verfaillie C.M. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001, 98:2615-2625.
81. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
82. D'Ippolito G., Diabira S., Howard G.A., Menei P., Roos B.A., Schiller P.C. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004, 117:2971-2981.
83. Kucia M., Reca R., Campbell F.R., Zuba-Surma E., Majka M., Ratajczak J., et al. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia 2006, 20:857-869.
84. D'Ippolito G., Diabira S., Howard G.A., Roos B.A., Schiller P.C. Low oxygen tension inhibits osteogenic differentiation and enhances stemness of human MIAMI cells. Bone 2006, 39:513-522.
85. Curtis K.M., Gomez L.A., Schiller P.C. Rac1b regulates NT3-stimulated Mek-Erk signaling, directing marrow-isolated adult multilineage inducible (MIAMI) cells toward an early neuronal phenotype. Mol Cell Neurosci 2012, 49:138-148.
86. Delcroix G.J., Curtis K.M., Schiller P.C., Montero-Menei C.N. EGF and bFGF pre-treatment enhances neural specification and the response to neuronal commitment of MIAMI cells. Differentiation 2010, 80:213-227.
87. Delcroix G.J., Garbayo E., Sindji L., Thomas O., Vanpouille-Box C., Schiller P.C., et al. The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats. Biomaterials 2011, 32:1560-1573.
88. Cowan K.H., Moscow J.A., Huang H., Zujewski J.A., O'Shaughnessy J., Sorrentino B., et al. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 1999, 5:1619-1628.
89. Hesdorffer C., Ayello J., Ward M., Kaubisch A., Vahdat L., Balmaceda C., et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998, 16:165-172.
90. Abonour R., Williams D.A., Einhorn L., Hall K.M., Chen J., Coffman J., et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000, 6:652-658.
91. Mitsuhashi J., Hosoyama H., Tsukahara S., Katayama K., Noguchi K., Ito Y., et al. In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med 2010, 12:596-603.
92. Mitsuhashi J., Tsukahara S., Suzuki R., Oh-hara Y., Nishi S., Hosoyama H., et al. Retroviral integration site analysis and the fate of transduced clones in an MDR1 gene therapy protocol targeting metastatic breast cancer. Hum Gene Ther 2007, 18:895-906.
93. Takahashi S., Aiba K., Ito Y., Hatake K., Nakane M., Kobayashi T., et al. Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients. Cancer Sci 2007, 98:1609-1616.
94. Chen H.L., Bai H. Transfection of gene mdr1 into human bone marrow mesenchymal stem cells by lentiviral vector. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009, 17:690-694.
95. Wang W.B., Liu Z.H., Zheng W.P., Sun L.Y. Method to transfect the mesenchymal stem cells from placenta by retrovirus taking MDR1 gene. Chin J Lab Diagn 2008, 12:857-859.
96. Ye M.Z., Han L.Y., Yue X., Li H.L. The transfection of multidrug resistance gene into mesenchymal stem cells derived from human bone marrow reinforcing the resistance to chemotherapy. Chin J Lab Diagn 2007, 11:10-12.
97. Gao ZB, Xei YH, Su SW, Geng JN, Cao XY, Wang Q. A novel drug delivery system for anti-cancer drug loaded nanoparticles. CHN Patent No. 201110165034.2.
98. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22:7468-7485.
99. Ho E.A., Soo P.L., Allen C., Piquette-Miller M. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J Control Release 2007, 117:20-27.
100. Sahoo S.K., Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2005, 2:373-383.
101. Chavanpatil M.D., Patil Y., Panyam J. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm 2006, 320:150-156.
102. Sahoo S.K., Ma W., Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 2004, 112:335-340.
103. Kidd S., Spaeth E., Dembinski J.L., Dietrich M., Watson K., Klopp A., et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009, 27:2614-2623.
104. Seo S.H., Kim K.S., Park S.H., Suh Y.S., Kim S.J., Jeun S.S., et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 2011, 18:488-495.
105. Yong R.L., Shinojima N., Fueyo J., Gumin J., Vecil G.G., Marini F.C., et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009, 69:8932-8940.
106. Polyak B., Fishbein I., Chorny M., Alferiev I., Williams D., Yellen B., et al. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci U S A 2008, 105:698-703.
107. Kim J.A., Lee H.J., Kang H.J., Park T.H. The targeting of endothelial progenitor cells to a specific location within a microfluidic channel using magnetic nanoparticles. Biomed Microdevices 2009, 11:287-296.
108. Wilhelm C., Bal L., Smirnov P., Galy-Fauroux I., Clement O., Gazeau F., et al. Magnetic control of vascular network formation with magnetically labeled endothelial progenitor cells. Biomaterials 2007, 28:3797-3806.
109. Kobayashi T., Ochi M., Yanada S., Ishikawa M., Adachi N., Deie M., et al. A novel cell delivery system using magnetically labeled mesenchymal stem cells and an external magnetic device for clinical cartilage repair. Arthroscopy 2008, 24:69-76.
110. Huang Z., Pei N., Wang Y., Xie X., Sun A., Shen L., et al. Deep magnetic capture of magnetically loaded cells for spatially targeted therapeutics. Biomaterials 2010, 31:2130-2140.
111. Francois S., Bensidhoum M., Mouiseddine M., Mazurier C., Allenet B., Semont A., et al. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells 2006, 24:1020-1029.
112. Momin E.N., Vela G., Zaidi H.A. Quinones-Hinojosa a. the oncogenic potential of mesenchymal stem cells in the treatment of cancer: directions for future research. Curr Immunol Rev 2010, 6:137-148.
113. Kim S.M., Kim D.S., Jeong C.H., Kim D.H., Kim J.H., Jeon H.B., et al. CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas. Biochem Biophys Res Commun 2011, 407:741-746.
114. Blakeley J., Portnow J. Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. Expert Opin Drug Metab Toxicol 2010, 6:1477-1491.
115. Dai L.J., Moniri M.R., Zeng Z.R., Zhou J.X., Rayat J., Warnock G.L. Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett 2011, 305:8-20.
116. Lu Y.R., Yuan Y., Wang X.J., Wei L.L., Chen Y.N., Cong C., et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 2008, 7:245-251.
117. Nakamura K., Ito Y., Kawano Y., Kurozumi K., Kobune M., Tsuda H., et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004, 11:1155-1164.
118. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
119. Xu W.T., Bian Z.Y., Fan Q.M., Li G., Tang T.T. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett 2009, 281:32-41.